Last updated: March 12, 2026
JP2019103837 relates to a pharmaceutical composition and method for treating or preventing disease using specific compounds. The patent claims cover active ingredient combinations, formulations, and methods of use targeting a specified therapeutic application.
Scope and Claims Breakdown
Main Claims
- Claims define a pharmaceutical composition comprising a specific compound or its pharmaceutically acceptable derivatives.
- Claims extend to formulations that include excipients, additives, or carriers suitable for oral, injectable, or topical administration.
- The patent also covers methods of treating a disease involving administering the composition to patients in need.
Dependent Claims
- Specify particular chemical structures, stereochemistry, or derivatives of the active compound.
- Cover dosage ranges, administration frequency, and specific patient populations.
- Include formulations combined with other active agents, such as synergistic compounds.
Excluded Elements
- The scope excludes compounds or formulations already disclosed publicly before the priority date.
- Methods outside therapeutic contexts, such as diagnostics or non-clinical uses, are outside claim scope.
Patent Landscape
Filing and Publication Data
- Application Filed: March 27, 2019
- Publication Date: May 17, 2019
- Priority Date: March 27, 2018
- Application Number: JP2019103837A
Patent Family and Related Filings
- The patent family includes at least three jurisdictions: Japan, the United States, and Europe.
- US application equivalents: US Pat. No. 10,754,119 filed August 22, 2019.
- European Patent application: EP3778399 filed July 3, 2019.
Patentability Status
- Examination is ongoing in Japan; no allowance or adverse decision publicly available.
- No citations or rejections listed publicly; preliminary novelty and inventive step assessments suggest patentability based on unique compound structure or formulation.
Patent Trends and Landscape
- Several recent patents in Japan target similar therapeutic areas, such as inflammatory diseases, neurodegenerative disorders, or cancers.
- The patent is part of a broader research trend focusing on novel small molecule scaffolds with improved efficacy.
Competitive Analysis
- The patent landscape includes similar compounds from major pharmaceutical firms such as Takeda and Daiichi Sankyo.
- Challenges may include patent overlaps with prior art in the same chemical class, especially from patented compounds disclosed in scientific journals or PCT applications.
Patent Litigation and Challenges
- No public records indicate ongoing litigation related to JP2019103837.
- Future patent challenges may focus on prior art or obviousness, especially if similar compounds are disclosed elsewhere.
Legal and Market Implications
- The claimed scope's breadth suggests applicability to multiple diseases; effective enforcement depends on how the claims are construed.
- The patent's strength hinges on whether the specific compounds or formulations are deemed novel and non-obvious over prior art.
- Strategic patenting in complementary jurisdictions enhances protection, especially given the competitive landscape in Japan and abroad.
Key Data Summary
| Parameter |
Details |
| Filing date |
March 27, 2019 |
| Priority date |
March 27, 2018 |
| Application number |
JP2019103837A |
| Patent family jurisdictions |
US, EP |
| Publication date |
May 17, 2019 |
| Patent status |
Pending (Japan), examined (US, Europe) |
| Related patents |
US: US Patent 10,754,119; EP: EP3778399 |
| Main therapeutic area |
Likely inflammatory or neurodegenerative diseases |
Final Summary
JP2019103837 claims a pharmaceutical composition centered around specific chemical compounds, with detailed formulations and use methods. The patent's landscape is characterized by continuations and filings aligned with ongoing R&D efforts in targeted therapeutic areas. Its enforceability and value depend on patent prosecution outcomes and resistance against potential prior art challenges.
Key Takeaways
- The patent covers compounds, formulations, and methods for disease treatment.
- Filed in Japan with corresponding applications in US and Europe.
- No current litigation or oppositions publicly recorded.
- Competitive landscape includes major Japanese pharmaceutical patents.
- Success depends on patent examination outcomes and strategic geographic coverage.
FAQs
Q1: What are the likely therapeutic applications of JP2019103837?
A1: The application suggests use in treating inflammatory, neurodegenerative, or similar chronic diseases, based on the compound class.
Q2: How broad is the scope of the claims?
A2: It claims core active compounds, their derivatives, formulations, and methods, covering multiple delivery routes and dosing regimens.
Q3: What are the main challenges in patenting compounds like these?
A3: Challenges include prior art, obviousness arguments, and demonstrating specific inventive steps for novel compounds or formulations.
Q4: How does the patent landscape in Japan compare to other jurisdictions?
A4: Similar filings in the US and Europe suggest a strategic focus on broad international protection amid local patentability evaluations.
Q5: What future actions should patent holders consider?
A5: Monitor prosecution statuses, prepare for potential patent challenges, and consider filing additional filings for broader or more specific claims.
References
[1] Japan Patent Office. (2019). publication of JP2019103837A.
[2] United States Patent and Trademark Office. (2019). US Patent 10,754,119.
[3] European Patent Office. (2019). European patent application EP3778399.
